Burak Arslan

Moelndal, O 40530, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Analytical Performance and Evaluation in Clinical Cohorts of a Fully Automated Immunoassay for Plasma Glial Fibrillary Acidic Protein.

Analytical Performance and Evaluation in Clinical Cohorts of a Fully Automated Immunoassay for Plasma Glial Fibrillary Acidic Protein.

Journal: Diagnostics (Basel, Switzerland)
Published: May 14, 2026

Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.

Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.

Journal: medRxiv : the preprint server for health sciences
Published: April 03, 2026

Real-world performance of Lumipulse G plasma p-tau217: a six-month experience of a specialized clinical neurochemistry laboratory.

Real-world performance of Lumipulse G plasma p-tau217: a six-month experience of a specialized clinical neurochemistry laboratory.

Journal: Clinical chemistry and laboratory medicine
Published: March 10, 2026

CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum.

CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum.

Journal: EBioMedicine
Published: January 22, 2026

Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.

Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.

Journal: NPJ Parkinson's disease
Published: January 17, 2026

Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.

Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 15, 2025

Analytical and clinical validation of the Lumipulse G plasma p-tau217 assay for clinical implementation.

Analytical and clinical validation of the Lumipulse G plasma p-tau217 assay for clinical implementation.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 26, 2025

Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization.

Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization.

Journal: Clinical chemistry and laboratory medicine
Published: September 11, 2025

Integrating kidney function assessment into the clinical interpretation of plasma Alzheimer's disease biomarkers.

Integrating kidney function assessment into the clinical interpretation of plasma Alzheimer's disease biomarkers.

Journal: Journal of Alzheimer's disease : JAD
Published: September 09, 2025

Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.

Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.

Journal: Nature communications
Published: July 23, 2025

Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation.

Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation.

Journal: Clinical chemistry and laboratory medicine
Published: July 11, 2025

Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?

Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?

Journal: Clinical chemistry
Published: June 16, 2025
Showing 1-12 of 34

Last Updated: 09/26/2026